Kamada Ltd. (NASDAQ:KMDA – Free Report) – Analysts at HC Wainwright reduced their FY2027 earnings per share (EPS) estimates for Kamada in a research report issued to clients and investors on Friday, August 14th. HC Wainwright analyst A. Fein now forecasts that the biotechnology company will post earnings of $0.56 per share for the year, down from their previous forecast of $0.64. The consensus estimate for Kamada’s current full-year earnings is $0.49 per share. HC Wainwright also issued estimates for Kamada’s FY2028 earnings at $0.69 EPS and FY2029 earnings at $0.74 EPS.
A number of other research firms have also recently commented on KMDA. Benchmark reissued a “buy” rating on shares of Kamada in a research report on Tuesday, July 21st. William Blair set a $15.00 price target on shares of Kamada in a report on Tuesday, July 21st. Wall Street Zen raised Kamada from a “hold” rating to a “strong-buy” rating in a research report on Saturday. Finally, Weiss Ratings lowered Kamada from a “buy (b)” rating to a “buy (b-)” rating in a report on Thursday, June 25th. Three analysts have rated the stock with a Buy rating, According to MarketBeat, the stock currently has a consensus rating of “Buy” and a consensus target price of $13.00.
Kamada Stock Up 1.7%
Shares of Kamada stock opened at $7.89 on Monday. The company has a market cap of $453.75 million, a P/E ratio of 20.76, a PEG ratio of 0.67 and a beta of 0.86. The firm’s 50 day moving average price is $7.25 and its 200-day moving average price is $7.94. Kamada has a 52-week low of $6.50 and a 52-week high of $9.35.
Kamada (NASDAQ:KMDA – Get Free Report) last released its quarterly earnings results on Wednesday, August 12th. The biotechnology company reported $0.16 EPS for the quarter, beating the consensus estimate of $0.11 by $0.05. Kamada had a net margin of 11.60% and a return on equity of 8.37%. The business had revenue of $54.92 million during the quarter, compared to analyst estimates of $50.84 million.
Kamada Cuts Dividend
The business also recently declared an annual dividend, which will be paid on Thursday, September 17th. Shareholders of record on Thursday, August 27th will be paid a dividend of $0.17 per share. The ex-dividend date is Thursday, August 27th. This represents a yield of 219.0%. Kamada’s dividend payout ratio is presently 50.00%.
Institutional Inflows and Outflows
A number of hedge funds and other institutional investors have recently made changes to their positions in KMDA. Marshall Wace LLP lifted its stake in shares of Kamada by 25.9% during the fourth quarter. Marshall Wace LLP now owns 196,954 shares of the biotechnology company’s stock worth $1,390,000 after buying an additional 40,514 shares during the period. Goldman Sachs Group Inc. raised its stake in Kamada by 43.3% in the 4th quarter. Goldman Sachs Group Inc. now owns 167,521 shares of the biotechnology company’s stock worth $1,183,000 after acquiring an additional 50,608 shares during the last quarter. Huntleigh Advisors Inc. raised its stake in Kamada by 5.5% in the 4th quarter. Huntleigh Advisors Inc. now owns 149,374 shares of the biotechnology company’s stock worth $1,055,000 after acquiring an additional 7,812 shares during the last quarter. Two Sigma Investments LP lifted its position in Kamada by 4.3% during the 3rd quarter. Two Sigma Investments LP now owns 109,589 shares of the biotechnology company’s stock worth $761,000 after acquiring an additional 4,504 shares during the period. Finally, Jane Street Group LLC acquired a new stake in Kamada during the 1st quarter worth about $582,000. Hedge funds and other institutional investors own 20.38% of the company’s stock.
Kamada News Roundup
Here are the key news stories impacting Kamada this week:
- Positive Sentiment: HC Wainwright raised its earnings outlook across multiple periods. The firm increased its Q3 2026 EPS estimate to $0.16 from $0.13, Q4 2026 to $0.13 from $0.10, and full-year 2026 to $0.52 from $0.41. Its FY2030 estimate rose to $1.11 from $0.88, signaling improved expectations for Kamada’s profitability and long-term growth.
- Positive Sentiment: Kamada declared a $0.17-per-share cash dividend. Investors of record on August 27 will receive the dividend on September 17, with the stock going ex-dividend on August 27. The distribution is consistent with Kamada’s cash-dividend policy and may support investor demand, although the share price will typically adjust downward by approximately the dividend amount on the ex-dividend date. Kamada Declares Cash Dividend of $0.17 Per Share
- Positive Sentiment: First-half 2026 results were described as record-high for revenue and profitability. The results provide fundamental support for the dividend and may help explain the more optimistic analyst forecasts. Kamada Declares $0.17 Dividend After Record-High First-Half 2026 Results
- Negative Sentiment: One analyst report maintained a pessimistic view of Kamada’s FY2027 earnings. While details were limited, the outlook suggests that some concerns remain about the pace or durability of earnings growth beyond 2026.
Kamada Company Profile
Kamada Ltd. is a biopharmaceutical company headquartered in Israel that specializes in the development, manufacturing and commercialization of plasma‐derived protein therapeutics. The company focuses on treatments for rare and serious diseases, leveraging its proprietary fractionation and purification technologies to produce purified human proteins. Kamada’s product portfolio addresses critical therapeutic areas in immunology, hematology and pulmonology, where alternative treatment options may be limited.
Among Kamada’s marketed products is Glassia®, an alpha‐1 antitrypsin augmentation therapy approved by the U.S.
Featured Articles
- Five stocks we like better than Kamada
- The AI Boom Is Turning This Cable Maker Into a Stock to Watch
- A Star Investor Just Trimmed Amazon—Here’s What It means
- Wendy’s Deal Buzz May Give Fast-Food Investors a New Reason to Look
- Home Depot Analysts See a Path to $375 and Beyond
Receive News & Ratings for Kamada Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kamada and related companies with MarketBeat.com's FREE daily email newsletter.
